{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Overall survival is defined as the time from date of diagnosis to death or date of last follow-up. 2-year overall survival is the probability of patients remaining alive at 2-years from study entry estimated using Kaplan-Meier (KM) methods which censors patients at date of last follow-up. Precision of this conditional probability estimate was measured in terms of standard error. Median OS, the original primary endpoint, was not estimable based on the Kaplan-Meier method because of insufficient follow-up.","groups":[{"description":"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51) Induction Chemotherapy: CT backbone of the IRS-III regimen \\[vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)\\] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.\n\nRadiation Therapy: Pts w/ M0 dz OR M+ dz aged \\<3y received focal RT (3D conformal or intensity-modulated delivery). Pts \\>3y w/ M+ dz rcvd craniospinal irradiation.\n\nContinuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively.","id":"OG000","title":"Multi-agent Intrathecal and Systemic CT With RT (Modified IRS"}],"paramType":"NUMBER","populationDescription":"The analysis dataset is comprised of all eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"Patients are followed for survival up to 5 yrs post-therapy completion or death; As of this analysis, median follow-up among survivors was 31 months with the longest follow-up being 40 months.","title":"2-yr Overall Survival","type":"PRIMARY","unitOfMeasure":"probability"}